AMAG Pharmaceuticals, Inc. Studies

Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*